Founded in 2010, Crystal Pharmatech has been recognized as the leading technology-driven contract research organization (CRO) in solid-state research, crystallization process development, and preformulation studies. As we continue to grow, Crystal Pharmatech will always keep customers our number one priority. We will also continue to be at the forefront of innovation in innovative drugs so that our customers can reap the benefits of fundamental discoveries in an ever-changing field.
Founded by Alex Chen, Yanfeng Zhang, and Robert Wenslow in Biobay, Suzhou Industrial Park (SIP), China, with a primary focus on solid-state research and pre-formulation development.
Secured $1.48 Million in Angel Round funding to accelerate growth.
Expanded R&D capabilities significantly, tripling the R&D space and establishing two R&D centers in New Jersery,USA and Suzhou, China respectively, providing solid-state research and pre-formulation services to international customers from both sites.
Achieved a significant milestone by raising $10 million in Series A Round funding.
Successfully secured $14.5 million in Series B Round funding.
Established a formulation development lab in Toronto, Canada, through its subsidiary, Candoo Pharmatech, thereby extending services to encompass formulation development.
Expanded service offerings to include formulation development, manufacturing, and clinical supply services through its fully-owned subsidiary, Crystal Formulation Services (CFS).
Established the Biologics Analytical Lab in New Jersey, USA.
The Biologics Analytical Lab in New Jersey, USA has spun out as Crystal Bio, with the vision of becoming the leading dedicated biologics analytical CRO in the USA.
A GMP facility in Toronto is under construction, enabling formulation development and manufacturing services from both Suzhou and Toronto sites.
